Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62601125 | 6260112 | 5 | F | 20160824 | 20070313 | 20160825 | EXP | IT-BRISTOL-MYERS SQUIBB COMPANY-13709290 | BRISTOL MYERS SQUIBB | 1.00 | DY | Y | 0.00000 | 20160825 | OT | IT | IT |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 62601125 | 6260112 | 1 | PS | EFAVIRENZ | EFAVIRENZ | 1 | Transplacental | UNK | Y | 20972 | CAPSULE | ||||||||
| 62601125 | 6260112 | 2 | C | LAMIVUDINE. | LAMIVUDINE | 1 | Transplacental | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 62601125 | 6260112 | 1 | HIV infection |
| 62601125 | 6260112 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 62601125 | 6260112 | OT |
| 62601125 | 6260112 | CA |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 62601125 | 6260112 | Foetal exposure during pregnancy | |
| 62601125 | 6260112 | Talipes |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |